Cytokinetics (CYTK) Convertible Debt (2019 - 2025)
Cytokinetics (CYTK) posted quarterly Convertible Debt of $889.5 million for Q3 2025, up 61.3% year-over-year from $551.5 million in Q3 2024, and up 60.57% quarter-over-quarter from $554.0 million in Q2 2025.
Cytokinetics (CYTK) Convertible Debt (2019 - 2025) Analysis & Trends
Cytokinetics (CYTK) has reported Convertible Debt for 7 consecutive years, with $889.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Convertible Debt rose 61.3% year-over-year to $889.5 million; the TTM figure through Sep 2025 stood at $889.5 million (up 61.3% YoY), while the FY2024 annual figure was $552.4 million, up 0.62% from the prior year.
- Convertible Debt advanced to $889.5 million in Q3 2025 per CYTK's latest filing, from $554.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $889.5 million in Q3 2025 and bottomed at $90.9 million in Q1 2021.
- Historically, Convertible Debt has averaged $427.6 million across 5 years, with a median of $547.3 million in 2023.
- Annual changes were most pronounced in 2022 — Convertible Debt surged 480.48% — and 2023, when it advanced 0.58%.
- Cytokinetics' Convertible Debt stood at $95.5 million in 2021, then jumped by 471.7% to $545.8 million in 2022, then grew by 0.58% to $549.0 million in 2023, then climbed by 0.62% to $552.4 million in 2024, then soared by 61.04% to $889.5 million in 2025.
- Business Quant data shows CYTK's Convertible Debt at $889.5 million in Q3 2025, $554.0 million in Q2 2025, and $553.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 889.52 Mn |
| Jun 30, 2025 | 553.99 Mn |
| Mar 31, 2025 | 553.14 Mn |
| Dec 31, 2024 | 552.37 Mn |
| Sep 30, 2024 | 551.48 Mn |
| Jun 30, 2024 | 550.60 Mn |
| Mar 31, 2024 | 549.79 Mn |
| Dec 31, 2023 | 548.99 Mn |
| Sep 30, 2023 | 548.13 Mn |
| Jun 30, 2023 | 547.29 Mn |
| Mar 31, 2023 | 546.51 Mn |
| Dec 31, 2022 | 545.81 Mn |
| Sep 30, 2022 | 544.99 Mn |
| Jun 30, 2022 | 134.67 Mn |
| Mar 31, 2022 | 134.51 Mn |
| Dec 31, 2021 | 95.47 Mn |
| Sep 30, 2021 | 93.89 Mn |
| Jun 30, 2021 | 92.35 Mn |
| Mar 31, 2021 | 90.89 Mn |
| Dec 31, 2020 | 89.50 Mn |